Canada - TSX:REUN - CA76134G1037 - Common Stock
The current stock price of REUN.CA is 1.42 CAD. In the past month the price decreased by -2.07%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 425.04M | ||
EDT.CA | SPECTRAL MEDICAL INC | N/A | 403.12M | ||
FRX.CA | FENNEC PHARMACEUTICALS INC | N/A | 342.31M | ||
HBP.CA | HELIX BIOPHARMA CORP | N/A | 183.31M | ||
BLU.CA | BLUENERGIES LTD | N/A | 171.18M | ||
MSCL.CA | SATELLOS BIOSCIENCE INC | N/A | 80.27M | ||
MDNA.CA | MEDICENNA THERAPEUTICS CORP | N/A | 78.41M | ||
NRX.CA | NUREXONE BIOLOGIC INC | N/A | 76.69M | ||
COV.CA | COVALON TECHNOLOGIES LTD | 25.12 | 55.11M | ||
SVA.CA | SERNOVA BIOTHERAPEUTICS INC | N/A | 44.58M | ||
MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 37.74M | ||
BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 32.30M |
Reunion Neuroscience, Inc. operates drug discovery and development business. The company is headquartered in Toronto, Ontario. The company went IPO on 2009-02-18. The firm is developing the advancement of synthetic molecules targeting serotonin 5HT2A receptors. The Company’s products include RE104 and RE200. The Company’s lead asset, RE-104, which is a psychedelic drug being developed for post-partum and treatment resistant depression as a potential fast-acting antidepressant with durable efficacy. The RE104 as a potentially fast-acting treatment for the key indications of postpartum and treatment resistant depression. The firm is developing the RE200 series, which includes compounds with potential for more selective serotonin receptor activity with reduced psych activity for potential use in more chronic treatment paradigms and indications. The firm is focused on the research and development of its RE200 molecule group.
Reunion Neuroscience Inc
30 Duncan Street, Suite 401
TORONTO ONTARIO CA
Employees: 0
Phone: 18338331967.0
The current stock price of REUN.CA is 1.42 CAD. The price decreased by -2.74% in the last trading session.
The exchange symbol of Reunion Neuroscience Inc is REUN and it is listed on the Toronto Stock Exchange exchange.
REUN.CA stock is listed on the Toronto Stock Exchange exchange.
8 analysts have analysed REUN.CA and the average price target is 1.02 CAD. This implies a price decrease of -28.17% is expected in the next year compared to the current price of 1.42. Check the Reunion Neuroscience Inc stock analysts ratings, price target forecast and up-and down grades for more detailed information.
Reunion Neuroscience Inc (REUN.CA) has a market capitalization of 16.64M CAD. This makes REUN.CA a Nano Cap stock.
Reunion Neuroscience Inc (REUN.CA) currently has 0 employees.
Reunion Neuroscience Inc (REUN.CA) has a support level at 1.41 and a resistance level at 1.46. Check the full technical report for a detailed analysis of REUN.CA support and resistance levels.
The Revenue of Reunion Neuroscience Inc (REUN.CA) is expected to decline by -100% in the next year. Check the estimates tab for more information on the REUN.CA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
REUN.CA does not pay a dividend.
Reunion Neuroscience Inc (REUN.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.13).
ChartMill assigns a technical rating of 4 / 10 to REUN.CA.
ChartMill assigns a fundamental rating of 3 / 10 to REUN.CA. While REUN.CA seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months REUN.CA reported a non-GAAP Earnings per Share(EPS) of -3.13. The EPS increased by 86.96% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | N/A | ||
ROE | N/A | ||
Debt/Equity | 0 |
8 analysts have analysed REUN.CA and the average price target is 1.02 CAD. This implies a price decrease of -28.17% is expected in the next year compared to the current price of 1.42.
For the next year, analysts expect an EPS growth of 47.21% and a revenue growth -100% for REUN.CA